Comparing OnKure Therapeutics (OKUR) & Its Competitors

OnKure Therapeutics (NASDAQ:OKUR) is one of 1,047 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare OnKure Therapeutics to similar companies based on the strength of its analyst recommendations, institutional ownership, earnings, risk, profitability, valuation and dividends.

Earnings & Valuation

This table compares OnKure Therapeutics and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
OnKure Therapeutics	N/A	-$77.39 million	-1.27
OnKure Therapeutics Competitors	$2.08 billion	$155.46 million	-5.55

OnKure Therapeutics’ competitors have higher revenue and earnings than OnKure Therapeutics. OnKure Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of recent ratings and price targets for OnKure Therapeutics and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	0	0	2	1	3.33
OnKure Therapeutics Competitors	7575	20829	48417	1188	2.55

OnKure Therapeutics presently has a consensus target price of $37.50, suggesting a potential upside of 142.09%. As a group, “Pharmaceutical preparations” companies have a potential upside of 75.44%. Given OnKure Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe OnKure Therapeutics is more favorable than its competitors.

Insider and Institutional Ownership

91.0% of OnKure Therapeutics shares are owned by institutional investors. Comparatively, 44.4% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 17.9% of OnKure Therapeutics shares are owned by company insiders. Comparatively, 13.8% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk and Volatility

OnKure Therapeutics has a beta of 0.21, meaning that its stock price is 79% less volatile than the S&P 500. Comparatively, OnKure Therapeutics’ competitors have a beta of 0.79, meaning that their average stock price is 21% less volatile than the S&P 500.

Profitability

This table compares OnKure Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-51.17%	-47.11%
OnKure Therapeutics Competitors	-3,620.42%	-274.38%	-33.56%

Summary

OnKure Therapeutics beats its competitors on 8 of the 12 factors compared.

OnKure Therapeutics Company Profile

Reneo Pharmaceuticals Inc.is a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Inc.is based in SAN DIEGO.